Total Payments
$159,440
2024 Payments
$442.20
Companies
46
Transactions
842
Medicare Patients
1,226
Medicare Billing
$277,981
Payment Breakdown by Category
Other$118,068 (74.1%)
Travel$20,894 (13.1%)
Food & Beverage$14,436 (9.1%)
Consulting$5,800 (3.6%)
Education$242.31 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $118,068 | 37 | 74.1% |
| Travel and Lodging | $20,894 | 25 | 13.1% |
| Food and Beverage | $14,436 | 754 | 9.1% |
| Consulting Fee | $5,800 | 13 | 3.6% |
| Education | $242.31 | 13 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $96,900 | 170 | $0 (2023) |
| Celgene Corporation | $39,366 | 65 | $0 (2022) |
| Genentech USA, Inc. | $13,234 | 35 | $0 (2022) |
| Merck Sharp & Dohme LLC | $1,436 | 76 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,136 | 76 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $1,058 | 65 | $0 (2023) |
| Amgen Inc. | $971.45 | 51 | $0 (2022) |
| PFIZER INC. | $697.06 | 46 | $0 (2023) |
| EISAI INC. | $616.45 | 27 | $0 (2022) |
| Bayer HealthCare Pharmaceuticals Inc. | $419.01 | 30 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $442.20 | 7 | Merck Sharp & Dohme LLC ($270.35) |
| 2023 | $10,382 | 19 | E.R. Squibb & Sons, L.L.C. ($9,923) |
| 2022 | $35,761 | 81 | E.R. Squibb & Sons, L.L.C. ($33,271) |
| 2021 | $14,376 | 83 | E.R. Squibb & Sons, L.L.C. ($13,253) |
| 2020 | $22,540 | 166 | E.R. Squibb & Sons, L.L.C. ($20,348) |
| 2019 | $31,082 | 156 | Celgene Corporation ($19,707) |
| 2018 | $26,564 | 175 | Celgene Corporation ($14,350) |
| 2017 | $18,292 | 155 | Genentech USA, Inc. ($13,104) |
All Payment Transactions
842 individual payment records from CMS Open Payments — Page 1 of 34
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/19/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $26.78 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $27.92 | General |
| Category: ONCOLOGY | ||||||
| 07/24/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $90.87 | General |
| 07/24/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $90.87 | General |
| 05/15/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $88.61 | General |
| Category: ONCOLOGY | ||||||
| 04/30/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $93.63 | General |
| Category: ONCOLOGY | ||||||
| 01/22/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $23.52 | General |
| Category: ONCOLOGY | ||||||
| 09/27/2023 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $112.11 | General |
| Category: Oncology | ||||||
| 08/15/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: Oncology | ||||||
| 08/07/2023 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $12.94 | General |
| Category: Oncology | ||||||
| 07/29/2023 | PFIZER INC. | BOSULIF (Drug) | Food and Beverage | In-kind items and services | $13.38 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 07/20/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $23.68 | General |
| Category: ONCOLOGY | ||||||
| 07/13/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.67 | General |
| 04/13/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $117.60 | General |
| Category: Oncology | ||||||
| 04/12/2023 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Oncology | ||||||
| 04/10/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $22.96 | General |
| Category: Oncology | ||||||
| 04/06/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $23.06 | General |
| 04/06/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $3.72 | General |
| 04/06/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $3.14 | General |
| 04/04/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $18.83 | General |
| Category: Oncology | ||||||
| 04/04/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological), ENHERTU | Food and Beverage | In-kind items and services | $4.04 | General |
| Category: Oncology | ||||||
| 02/28/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $9,893.00 | General |
| Category: Oncology | ||||||
| 02/03/2023 | PFIZER INC. | IBRANCE (Drug), XTANDI, ORGOVYX | Food and Beverage | In-kind items and services | $13.66 | General |
| Category: ONCOLOGY | ||||||
| 02/01/2023 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $20.65 | General |
| Category: Oncology | ||||||
| 01/06/2023 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $20.07 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 130 | 144 | $30,121 | $14,500 |
| 2022 | 4 | 284 | 463 | $114,267 | $51,507 |
| 2021 | 9 | 286 | 1,609 | $205,008 | $52,706 |
| 2020 | 14 | 526 | 43,376 | $487,974 | $159,267 |
Total Patients
1,226
Total Services
45,592
Medicare Billing
$277,981
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 53 | 60 | $13,140 | $7,899 | 60.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 32 | 38 | $8,232 | $2,828 | 34.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 17 | 17 | $4,893 | $1,852 | 37.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 16 | 17 | $2,716 | $1,596 | 58.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 12 | 12 | $1,140 | $325.56 | 28.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 149 | 313 | $83,738 | $37,905 | 45.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 89 | 104 | $18,981 | $8,292 | 43.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 34 | 34 | $11,356 | $5,221 | 46.0% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Facility | 2022 | 12 | 12 | $192.00 | $89.40 | 46.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 120 | 260 | $119,600 | $30,606 | 25.6% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 23 | 124 | $46,004 | $11,917 | 25.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 27 | 27 | $15,120 | $4,216 | 27.9% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2021 | 18 | 187 | $8,041 | $2,226 | 27.7% |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | Office | 2021 | 17 | 76 | $6,156 | $1,699 | 27.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 19 | 19 | $6,251 | $1,099 | 17.6% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 26 | 81 | $2,916 | $793.87 | 27.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2021 | 18 | 750 | $750.00 | $91.95 | 12.3% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2021 | 18 | 85 | $170.00 | $56.90 | 33.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 173 | 611 | $205,296 | $60,582 | 29.5% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2020 | 21 | 108 | $81,540 | $32,687 | 40.1% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 40 | 236 | $72,216 | $22,652 | 31.4% |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 2020 | 15 | 39,240 | $39,240 | $15,577 | 39.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 50 | 50 | $23,900 | $7,244 | 30.3% |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | Office | 2020 | 32 | 213 | $14,697 | $4,687 | 31.9% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2020 | 33 | 396 | $14,256 | $4,611 | 32.3% |
About Dr. Simeon Jaggernauth, DO
Dr. Simeon Jaggernauth, DO is a Medical Oncology healthcare provider based in Tulsa, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1083667737.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Simeon Jaggernauth, DO has received a total of $159,440 in payments from pharmaceutical and medical device companies, with $442.20 received in 2024. These payments were reported across 842 transactions from 46 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($118,068).
As a Medicare-enrolled provider, Jaggernauth has provided services to 1,226 Medicare beneficiaries, totaling 45,592 services with total Medicare billing of $277,981. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Medical Oncology
- Location Tulsa, OK
- Active Since 05/17/2006
- Last Updated 05/30/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1083667737
Products in Payments
- OPDIVO (Biological) $93,905
- Abraxane (Drug) $37,339
- Avastin (Biological) $12,971
- KEYTRUDA (Biological) $1,096
- Lenvima (Drug) $599.62
- Revlimid (Drug) $381.37
- KISQALI (Drug) $329.48
- IMFINZI (Drug) $328.97
- LIBTAYO (Biological) $296.25
- Tavalisse (Drug) $274.60
- MEKINIST (Drug) $268.60
- Neulasta (Biological) $258.11
- Cabometyx (Drug) $251.35
- IBRANCE (Drug) $246.37
- IMFINZI (Biological) $219.09
- CYRAMZA (Drug) $218.20
- Xofigo (Drug) $198.37
- Udenyca (Biological) $194.17
- INLYTA (Drug) $192.83
- BRUKINSA (Drug) $184.81
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.